Rana Divya, Kumar Anoop
Department of Pharmacology, Indo-Soviet Friendship Pharmacy College (ISFCP), Moga, Punjab, India.
Curr Diabetes Rev. 2019;15(4):284-287. doi: 10.2174/1573399814666180903162556.
Diabetes is a metabolic disorder, whose incidences are increasing day by day. Various classes of anti-diabetic drugs are clinically approved by the Food and Drug Administration (FDA) for the treatment of diabetes mellitus, but unfortunately, none of them is able to treat this condition. Thus, the exploration of novel mechanistic pathways of existing molecules may help to develop more safe and effective anti-diabetic agents. Sodium orthovanadate is a well known common laboratory agent used to preserve the protein tyrosyl phosphorylation state of the protein.
The data related to sodium orthovanadate and diabetes mellitus has been collected from Pubmed.
Various reports have indicated the potential of sodium orthovanadate as Protein Tyrosine Phosphatase (PTP1B) inhibitors which play an important role in the pathogenesis of diabetes. However, safety of Sodium orthovanadate is still questionable.
The sodium orthovanadate could be developed as an anti-diabetic agent. However, further studies are required to confirm its safety profile in the treatment of diabetes mellitus before starting a clinical trial.
糖尿病是一种代谢紊乱疾病，其发病率日益增加。各类抗糖尿病药物已获美国食品药品监督管理局（FDA）临床批准用于治疗糖尿病，但遗憾的是，尚无一种药物能够治愈该疾病。因此，探索现有分子的新作用机制途径可能有助于开发更安全有效的抗糖尿病药物。原钒酸钠是一种广为人知的常见实验室试剂，用于维持蛋白质的酪氨酸磷酸化状态。
从PubMed收集了与原钒酸钠和糖尿病相关的数据。
各种报告表明原钒酸钠具有作为蛋白酪氨酸磷酸酶（PTP1B）抑制剂的潜力，而PTP1B在糖尿病发病机制中起重要作用。然而，原钒酸钠的安全性仍存在疑问。
原钒酸钠有望开发成为一种抗糖尿病药物。然而，在开展临床试验之前，还需要进一步研究以确认其治疗糖尿病时的安全性。
